Search clinical trials for: olaparib

Total 429 results

University of Cologne
AstraZeneca

Not yet recruiting

Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC) (GUIDANCE)

Small Cell Lung Carcinoma
AstraZeneca
Merck Sharp & Dohme LLC

Recruiting

Real-World Clinical Experience of Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Olaparib + Abiraterone (PROceed) (PROceed)

Metastatic Castration-resistant Prostate Cancer

Germany
Vall d'Hebron Institute of Oncology

Recruiting

Status of HRD That Lead to a Benefit From Olaparib in Combination With Bevacizumab (STROBE Trial) (STROBE)

Ovarian Cancer

Spain
Merck Sharp & Dohme LLC
Orion Corporation, Orion Pharma

Recruiting

Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)

Prostatic Neoplasms, Castration-Resistant

Israel, Taiwan
University Health Network, Toronto
Centre for Addiction and Mental Health

Recruiting

Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: Comparing One Versus Two Doses of Psilocybin (PSI-1V2)

Depression | Mood Disorders | Major Depressive Disorder | Treatment-Resistant Depression

Canada
Jiangsu Simcere Pharmaceutical Co., Ltd.
Shanghai Xianxiang Medical Technology Co., Ltd.

Recruiting

Study of SIM0501 Alone and in Combination in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
AstraZeneca

Recruiting

Assessment of Safety of Olaparib in Chinese Patients With Ovarian Cancer in the Real-World Setting

Using NCID Database to Assess the Safety of Olaparib in Chinese Patients With Ovarian Cancer by Examining the Incidence, Seriousness, and Severity of All AE

China
Gustave Roussy, Cancer Campus, Grand Paris
Daiichi Sankyo

Recruiting

Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd (ICARUSBREAST02)

Advanced Breast Cancer | HER2-positive Metastatic Breast Cancer | Breast Cancer Metastatic | HER2 Low Breast Carcinoma

France
Sidney Kimmel Comprehensive Cancer Center at Johns...

Recruiting

PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC (NeoADAPT)

Triple Negative Breast Cancer

United States
Sichuan University

Recruiting

Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC

Lung Cancer | Extensive-stage Small-cell Lung Cancer

China
Pamela Munster
National Cancer Institute (NCI)

Recruiting

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

BRCA1 Mutation | BRCA2 Mutation | PALB2 Gene Mutation | ATM Gene Mutation | BRCA Mutation | Checkpoint Kinase 2 Gene Mutation

United States
National Cancer Centre, Singapore
Merck Sharp & Dohme LLC; National Medical Research Council (NMRC), Singapore

Not yet recruiting

Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma (POLAR)

Refractory Peripheral T-Cell Lymphoma | Relapsed Peripheral T-Cell Lymphoma

Singapore
M.D. Anderson Cancer Center
Mirati Therapeutics Inc.

Recruiting

Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers

Advanced Solid Tumor | Non-small Cell Lung Cancers

United States
Mario Negri Institute for Pharmacological Research
AstraZeneca

Recruiting

First Line Treatment With Olaparib in Combination With Bevacizumab in HRD Positive Patients (IOLANTHE)

Carcinoma, Ovarian Epithelial

Italy
Alexander B Olawaiye, MD
AstraZeneca

Recruiting

Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency

Ovarian Cancer

United States
Gustave Roussy, Cancer Campus, Grand Paris
Merck Sharp & Dohme LLC

Not yet recruiting

Study Evaluating Pembrolizumab +/- Olaparib in TLS Positive Selected Resectable STS Followed by Adjuvant Pembrolizumab (NeoSarc)

Cancer

France
AstraZeneca
Daiichi Sankyo

Recruiting

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

Breast Cancer

Spain, China, United States, Italy, United Kingdom, Korea, Republic of, Belgium, France, Germany, Poland, Japan, Vietnam, Canada, Brazil, India, Malaysia, Taiwan, Thailand, Australia, Austria, Turkey, Hong Kong, Bulgaria, Switzerland, H... and more
Azienda Ospedaliero-Universitaria di Modena

Recruiting

Olaparib in PALB2 Advanced Pancreatic Cancer (PALBOLA)

Metastatic Pancreatic Cancer | Advanced Pancreatic Cancer

Italy
Tango Therapeutics, Inc.

Recruiting

Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors

Breast Cancer | Ovarian Cancer | Prostate Cancer | Pancreas Cancer | BRCA1 Mutation | BRCA-Mutated Ovarian Carcinoma | BRCA-Associated Breast Carcinoma | HRD Positive Advanced Ovarian Cancer

United States
AstraZeneca

Recruiting

PRostate Olaparib Real World Evidence Study (PROWESs)

Metastatic Castration-resistant Prostate Cancer

France
Tianjin Medical University Cancer Institute and...

Recruiting

Study of Selinexor Combined With Olaparib in Relapsed/Refractory Extensive Stage Small Cell Lung Cancer

Extensive-stage Small Cell Lung Cancer

China
University of Alabama at Birmingham
Merck Sharp & Dohme LLC

Not yet recruiting

Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro

Ovarian Cancer

United States
University Medical Center Groningen

Not yet recruiting

OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults (OPTI-DOSE)

Renal Cell Carcinoma | Breast Carcinoma | Thyroid Carcinoma | Ovarian Carcinoma | Endometrium Carcinoma

Netherlands
Exelixis

Recruiting

A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients With Advanced Solid Tumors

Advanced Solid Tumor

United States
Mary D Chamberlin
Dartmouth-Hitchcock Medical Center

Not yet recruiting

Estradiol Plus Olaparib for Breast Cancer (PHOEBE) (PHOEBE)

Metastatic Breast Cancer
Artios Pharma Ltd

Recruiting

Study of ART6043 in Advanced/Metastatic Solid Tumors Patients

Advanced Solid Tumor | Metastatic Solid Tumor

United States
University of Colorado, Denver
ImmunoGen, Inc.

Recruiting

An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

Fallopian Tube Cancer | Peritoneal Cancer | Ovary Cancer

United States
Erasmus Medical Center

Recruiting

Improving Peptide Receptor Radionuclide Therapy With PARP Inhibitors (PRRT-PARPi)

Neuroendocrine Tumors | Peptide Receptor Radionuclide Therapy

Netherlands
COMPASS Pathways

Recruiting

A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder

Major Depressive Disorder

United States
Onxeo

Recruiting

Study To Assess Safety And Efficacy Of AsiDNA In Combination With Olaparib In Participants With Recurrent Solid Tumors

Breast Cancer | Metastatic Castration-resistant Prostate Cancer | Recurrent Epithelial Ovarian Cancer

United States
Spanish Cooperative Group for the Treatment of...
AstraZeneca

Recruiting

Olaparib and Durvalumab (MEDI4736) in Patients With Metastatic Pancreatic Cancer and DNA Damage Repair Genes Alterations

Metastatic Pancreatic Cancer

Spain
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working

Locally Advanced Leiomyosarcoma | Metastatic Leiomyosarcoma | Stage III Uterine Corpus Leiomyosarcoma AJCC v8 | Stage IV Uterine Corpus Leiomyosarcoma AJCC v8 | Unresectable Leiomyosarcoma | Uterine Corpus Leiomyosarcoma

United States
National Taiwan University Hospital
AstraZeneca

Recruiting

Olaparib Maintenance Therapy in Metastatic Breast Cancer

Metastatic Breast Cancer

Taiwan
Istituto Scientifico Romagnolo per lo Studio e...
Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC) (THOR)

SCLC,Extensive Stage

Italy
Rennes University Hospital

Recruiting

Microsampling Approach for Monitoring of Kinase Inhibitor Targeted Therapies (MISTIK)

Blood Concentrations of Nine Anti-cancer Drugs : Axitinib, Olaparib, regorafénib, Cabozantinib, Niraparib, Talazoparib, Palbociclib, Abemaciclib, Tucatinib

France
Zin W Myint
Merck Sharp & Dohme LLC

Recruiting

Pembro With Radiation With or Without Olaparib

Prostate Cancer

United States
Fondazione Ricerca Traslazionale

Recruiting

Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab

Non-small-cell Lung Cancer Patients

Italy
National Cancer Institute (NCI)

Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

Anatomic Stage III Breast Cancer AJCC v8 | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Anatomic Stage IV Breast Cancer AJCC v8 | Advanced Malignant Solid Neoplasm | Locally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid... and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Carcinoma

United States, Puerto Rico
Seoul National University Hospital

Not yet recruiting

Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 Inhibitor (Post-CDK)

Advanced Breast Cancer

Korea, Republic of
H. Lee Moffitt Cancer Center and Research Institute
Merck Sharp & Dohme LLC

Recruiting

Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma

Ocular Melanoma | Uveal Melanoma

United States
Hebei Medical University Fourth Hospital

Not yet recruiting

Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer

Solid Tumor
Sidney Kimmel Comprehensive Cancer Center at Johns...
AstraZeneca; The Marcus Foundation; McGuff Pharmaceuticals, Inc.

Recruiting

Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer

Prostate Cancer | Castration-resistant Prostate Cancer

United States
Rana McKay, MD
University of California, San Diego; AstraZeneca

Recruiting

Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With BRCA1/2 Gene Alterations (NePtune)

Prostate Cancer | BRCA1 Mutation | BRCA2 Mutation | Prostatic Adenocarcinoma | High-Risk Cancer

United States
Okayama University
Merck Sharp & Dohme LLC

Recruiting

Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer

Breast Cancer | Breast Neoplasms | Triple Negative Breast Cancer | Triple Negative Breast Neoplasms | BRCA1 Mutation | BRCA2 Mutation | BRCA Mutation | BRCA-Associated Breast Carcinoma

Japan
L. Nicolas Gonzalez Castro, MD, PhD
Merck Sharp & Dohme LLC

Recruiting

Surgical Pembro +/- Olaparib w TMZ for rGBM

Glioblastoma | Recurrent Glioblastoma

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

First-line Olaparib Combined With Bevacizumab Maintenance Therapy

Ovarian Neoplasms
AHS Cancer Control Alberta
Tom Baker Cancer Centre

Recruiting

Pilot Trial for Treatment of Recurrent Glioblastoma

Glioblastoma | Recurrent Glioblastoma | Recurrent Disease

Canada
University of Utah
Repare Therapeutics

Recruiting

RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia (CORONADO CLL)

Chronic Lymphocytic Leukemia

United States
University of Colorado, Denver
Merck Sharp & Dohme LLC

Recruiting

Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers

Gastric Cancer | GastroEsophageal Cancer

United States

Search clinical trials for: olaparib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mongolia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations